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Abstract
Purpose: To describe a case of infiltrative optic neuropathy caused by chronic
lymphocytic leukemia.
Case Report: A 41-year-old white male presented with painless, blurry vision in the
left eye. Examination revealed unilateral optic nerve swelling confirmed by optical
coherence tomography (OCT). Initial workup revealedmild leukocytosis, eventually diag-
nosed as chronic lymphocytic leukemia (CLL). No other cause of optic neuropathy was
identified despite extensive investigation. The patient developed rapidly progressive
retinal ganglion cell nerve fiber layer (NFL) atrophy and relative afferent pupillary defect
(RAPD) of the left eye despite steroid treatment but stabilized after four cycles of CLL-
targeted chemotherapy. Although infiltrative optic neuropathy is well-known in leukemia,
presentation with only subtle vision loss is rare. Vision loss usually presents late in
leukemic infiltrative optic neuropathy and therefore must be considered in patients with
optic disc swelling and leukocytosis.
Conclusion: When treating CLL, progressive visual decline with coexistent optic
neuropathy may warrant chemotherapy.
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Optic neuropathy is the consequence of several
pathologies including infection, systemic and local-
ized inflammation, demyelinating disorders, and
infiltrative conditions; however, it is most commonly
the result of demyelination.[1] Inflammatory neuritis
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usually presents as unilateral decreased vision with
pain on ocular movement, but other neuropathies
are frequently painless.[2–4] Visual prognosis often
depends on etiology and implementation of tar-
geted treatment. It is therefore imperative to make
all efforts to identify the cause; however, complex
and mostly similar presentations of optic neuropa-
thy makes the diagnosis difficult.[3, 5] Chronic lym-
phocytic leukemia (CLL) is a neoplastic expansion
of B cells colonizing lymphoid tissues. In 2014,
it was one of the most prevalent lymphoprolifer-
ative disorders in the United States, diagnosed
at an observed incidence of 7.1 per 100,000
males according to the Surveillance, Epidemiology,
and End Results (SEER) Program of the National
Cancer Institute.[1, 2, 6] Neuropathy caused by CLL
via hematogenous infiltration of the optic nerve
remains poorly described in literature with no clear
guidelines for its management.[1] Here, we present
a case of a young male patient who was diagnosed
with CLL following a subtle blurry scotoma; vision
loss was stabilized following the treatment of his
CLL.
CASE REPORT
A 41-year-old white male was referred to us for the
evaluation of painless blurry vision in his left eye
which had progressed gradually over the course
of one month. The patient reported a constant
inferonasal area of blurry vision with both near and
distance vision. Otherwise, he had unremarkable
ocular, medical, and surgical histories. He was an
ex-cigarette smoker. He had a family history of non-
melanoma skin cancer in his mother and multiple
sclerosis in one distant relative. His review of sys-
tems, including additional neurological symptoms,
was unremarkable.
At the time of presentation, central visual acuity
was 20/15 in his right eye (OD) and 20/25 in
his left eye (OS). There was no overt dyschro-
matopsia on isochromatic color plates, although
he had some difficulty reading the plates with
his left eye. His pupils were equal and reactive
without relative afferent pupillary defect (RAPD).
Funduscopic examination of his left eye revealed
inferior disc swelling which had not been present
three years prior in his previous ophthalmologic
exam. The initial laboratory results for unilateral
optic nerve swelling included erythrocyte sed-
imentation rate (ESR), C-reactive protein (CRP),
antinuclear antibody (ANA), angiotensin converting
enzyme (ACE), rapid plasma reagin (RPR) levels,
complete blood count (CBC), human immunod-
eficiency virus (HIV) titers, Bartonella antibody
titers, Lyme disease panels, and herpetic viral
panels. The results were normal except leuko-
cytosis (19.7 TH/𝜇L) with atypical lymphocytosis
(74%) noted as abundant smudge cells. Serum
polymerase chain reactions (PCR) for Epstein-Barr
and cytomegalovirus were negative. Magnetic res-
onance imaging (MRI) of his brain and orbits, with
and without contrast, was unremarkable. Static
visual field testing (Humphrey Visual Fields: HVF)
revealed an inferior scotoma in the left eye respect-
ing the horizontal meridian. Initial color fundus
photography [Figure 1] and Fourier-domain optical
coherence tomography (OCT, Figure 2(a)) of the
left eye showed inferior nerve fiber layer (NFL)
swelling beyond his age-appropriate norm. The
patient was admitted to the neurology ward for
full workup and inpatient hematology consulta-
tion.
Collected cerebrospinal fluid (CSF) analyses,
including opening pressure, infectious, autoim-
mune, and routine studies, were unremarkable.
Repeat CBC with manual slide review confirmed
the presence of leukocytosis with lymphocytic
predominance, and fluorescent in situ hybridization
(FISH) revealed 13q14 deletion. Flow cytometry
showed monoclonal CD5+/CD10-B cell population
consistent with CLL, classified as Rai stage 0/Binet
stage A with favorable cytogenetic studies. Visual
evoked potential was normal OD (106 milliseconds)
but minimally prolonged OS (113 milliseconds).
According to the National Comprehensive Cancer
Network (NCCN) guidelines, the patient was not
immediately treated for his CLL and was prescribed
prednisone for suspected atypical infiltrative optic
neuropathy.
One month after discharge, the patient reported
stability of his left eye blurry scotoma without
involvement of the right eye. He again denied
focal neurologic symptoms. Physical examination
showed stable central visual acuity, but identified
new onset left RAPD; funduscopic examination re-
demonstrated the left optic nerve inferior swelling
unchanged from the previous exam. Static visual
field testing showed slight worsening of his left
eye inferior nasal scotoma and OCT revealed
significant progression of NFL loss [Figure 2(b)].
Following discussions with our colleagues in the
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Figure 1. Color Fundus Photography taken at the Presentation. Disc margins are blurred along inferior border OS.
Figure 2. Static Perimetry Visual Field Testing with corresponding Optical Coherence Tomography Topographies. (A) Initial OS
scotoma along inferior field on HVF 24-2 testing with corresponding baseline NFL thickness collected at the time of presentation.
(B) Second visit HVF shows persistent scotoma and rapid NFL thinning compared to the baseline. (C) HVF during FR chemotherapy
shows possible improvement of scotoma and arrest of NFL loss. (D) HVF several weeks post chemotherapy shows improvement
in scotoma OS with stabilization of NFL loss compared to the baseline.
hematology department and extensive literature
review, chemotherapy was initiated.
During the patient’s first two cycles of FR
chemotherapy, he noted no visual decline nor
progression of his blurry vision scotoma. OCT
during this time showed stabilization of the NFL
without further loss [Figure 2(c)]. After four cycles
of chemotherapy with continued stabilization of
nerve fiber loss on OCT, and without progression
of his scotoma size or density on HVF, we decided
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to monitor him according to the NCCN guidelines
without further chemotherapy.
DISCUSSION
The differential diagnosis for optic neuropathy
encompasses a wide range of systemic
inflammatory, infectious, toxic, and inheritable
diseases.[1, 2, 5, 7] The landmark Optic Neuritis
Treatment Trial (ONTT) identified MRI as one
of the most powerful tools in diagnosing
optic neuritis; however, the identification of
small inflammatory lesions can be limited by
the resolution and sectioning of the MRI.[5, 8]
Therefore, atypical optic neuritis must be
considered even in the absence of MRI
findings. In many cases, identifying the cause
of optic neuropathy is a difficult endeavor.[3, 5]
Extramedullary involvement of CLL is rare in
reported literature, and due to the destructive
nature of tissue sampling, optic nerve infiltration
by atypical lymphocytes cannot be proven
without postmortem biopsy.[1, 2, 9] Even if the
presence of CLL cells in the nervous system
tissue is confirmed on biopsy, the presence
of ”bystander lymphocytes” can confound a
presumed causative relationship.[2] Infiltrative
optic neuropathy by CLL has rarely been
described in literature and these cases carry
a higher risk of permanent unrecoverable loss
of acuity, partially due to delay in diagnosis and
treatment.[1, 9] We believe that the response to
CLL treatment demonstrated by this patient, the
absence of significant findings on imaging, and
the exclusion of more common conditions as
noted earlier corroborates that infiltrative CLL
played a causative role in his optic neuropathy.
Our observations also suggest that CLL treatment,
including radiotherapy, should be considered in
patients with suspected optic nerve infiltration
to preserve vision, even if it is not indicated by
genotyping.[9]
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